Inclusion Criteria:

1. Patients with intermediate-1 risk MDS or transfusion dependent low risk MDS by the
IPSS classification. Patient must have one or more cytopenia as defined by IPSS
(Cytopenias are defined as an absolute neutrophil count < 1800 K/uL; or hemoglobin <
10 g/dl or platelets < 10^5 K/uL).

2. Signed informed consent indicating that patients are aware of the investigational
nature of this study prior to participation in the study and any related procedures
being performed.

3. Age >/= 18 years old

4. Prior therapy with growth factor support, lenalidomide, 5-azacytidine, decitabine or
other investigational agents is allowed if last dose was given more than 14 days
prior to first dose of LBH 589.

5. Previously untreated patients are eligible for this study.

6. Patients must meet the following laboratory criteria: AST/SGOT and ALT/SGPT upper limit of normal (ULN) or leukemic involvement; Serum bilirubin or 24-hour creatinine clearance >/= 50 ml/min; Serum potassium >/= lower limit of
normal (LLN); Serum phosphorous >/= LLN; Serum total calcium (corrected for serum
albumin) or serum ionized calcium >/= LLN; Serum magnesium >/= LLN; TSH and free T4
within normal limits (WNL) (patients may be on thyroid hormone replacement)

7. Baseline MUGA or ECHO must demonstrate LVEF >/= the lower limit of the institutional
normal of 50%.

8. ECOG Performance Status of
9. Women of childbearing potential (WOCBP) defined as not post-menopausal for 12 months
or no previous surgical sterilization must have a negative serum pregnancy test
within 72 hours of the first administration of oral LBH589.

10. Male patients who agree to use a condom during sexual contact with a female of child
bearing potential.

11. Patients with a heart rate >/= 50 beats per minute with or without a pacemaker.

Exclusion Criteria:

1. Prior treatment with an HDAC inhibitor for MDS or any other malignancy.

2. Patients currently treated with valproic acid for neurological or other conditions
who can not be changed to another therapy.

3. Impaired cardiac function including any one of the following: Screening ECG with QTc
> 450 msec confirmed by central laboratory prior to enrollment in study; Pts with
congenital long QT syndrome; History of sustained ventricular tachycardia; History of
ventricular fibrillation or torsades de pointes; Pts with myocardial infarction or
unstable angina within 6 mo. of study entry; Congestive heart failure; Right bundle
branch block with left anterior hemiblock (bifascicular block)

4. Concomitant use of drugs with a risk of causing torsades de pointes. A wash-out
period of at least 72 hours is required. Patients using medications that have a
relative risk of prolonging the QT interval or inducing torsades de pointes if
treatment cannot be discontinued or switched to a different medication prior to
starting study drug.

5. Concomitant use of CYP3A4 inhibitors. A wash-out period of at least 72 hours is
required.

6. Patients with unresolved diarrhea greater than CTCAE grade 1

7. Patients who have undergone major surgery less than 4 weeks prior to screening visit
or who have not recovered from side effects of such therapy.

8. Patients who have received chemotherapy, any investigational drug or undergone major
surgery within 3 weeks prior to starting study drug or who have not recovered from
side effects of such therapy (CTCAE Grade 1), with the exception of nitrosoureas,
which should be discontinued at least six weeks before enrollment.

9. Concomitant use of any anti-cancer therapy or radiation therapy.

10. Patients with a history of another primary malignancy within 5 years other than
curatively treated CIS of the cervix, or basal or squamous cell carcinoma of the skin

11. Patients with known positivity for human immunodeficiency virus (HIV) ) or hepatitis
C.

12. Patients with any significant history of non-compliance to medical regimens or with
inability to grant a reliable informed consent

13. Female patients who are pregnant or breastfeeding.

14. Uncontrolled hypertension, history of labile hypertension, or history of poor
compliance with an antihypertensive regimen.

15. Impairment of GI function or GI disease that may significantly alter the absorption
of LBH589

16. Peripheral neuropathy greater than CTCAE grade 2